Abstract
Oral tyrosine-kinase inhibitors (TKIs) improve clinical outcome in patients with chronic myeloid leukaemia, non-Hodgkin lymphomas, gastrointestinal stromal tumours (GIST), and breast cancer who have activating mutations, translocations, or fusions in dominant oncogenes. Epidermal growth factor receptor (EGFR) TKIs and anaplastic large-cell kinase (ALK) TKIs show a clinically significant effect in patients with non-small-cell lung cancer (NSCLC) who have EGFR mutations or ALK-EML4 translocations, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
